Srđan Verstovšek

57.7k total citations · 3 hit papers
1.1k papers, 30.0k citations indexed

About

Srđan Verstovšek is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Srđan Verstovšek has authored 1.1k papers receiving a total of 30.0k indexed citations (citations by other indexed papers that have themselves been cited), including 847 papers in Genetics, 782 papers in Hematology and 282 papers in Rheumatology. Recurrent topics in Srđan Verstovšek's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (681 papers), Chronic Myeloid Leukemia Treatments (502 papers) and Acute Myeloid Leukemia Research (363 papers). Srđan Verstovšek is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (681 papers), Chronic Myeloid Leukemia Treatments (502 papers) and Acute Myeloid Leukemia Research (363 papers). Srđan Verstovšek collaborates with scholars based in United States, United Kingdom and Italy. Srđan Verstovšek's co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Guillermo Garcia‐Manero, Francis J. Giles, Stefan Faderl, Susan O’Brien, Deborah A. Thomas, Ruben A. Mesa, Zeev Estrov and Alessandra Ferrajoli and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and The Journal of Experimental Medicine.

In The Last Decade

Srđan Verstovšek

1.0k papers receiving 29.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

2010 847 citations Srđan Verstovšek, Hagop M. Kantarjian et al. profile →
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

2007 604 citations Ayalew Tefferi, Jüergen Thiele et al. Blood profile →
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

2015 594 citations Alessandro M. Vannucchi, Jean‐Jacques Kiladjian et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Srđan Verstovšek United States	84	18.7k	18.6k	12.1k	8.5k	4.4k	1.1k	30.0k
Giuseppe Saglio Italy	75	13.4k 0.7×	18.5k 1.0×	5.6k 0.5×	7.0k 0.8×	4.3k 1.0×	650	25.0k
Mario Cazzola Italy	73	15.1k 0.8×	17.6k 0.9×	9.2k 0.8×	4.4k 0.5×	2.3k 0.5×	428	25.3k
Michele Baccarani Italy	80	14.6k 0.8×	20.3k 1.1×	4.9k 0.4×	8.1k 1.0×	5.9k 1.4×	711	29.1k
John M. Goldman United Kingdom	83	14.3k 0.8×	22.2k 1.2×	5.1k 0.4×	8.6k 1.0×	5.1k 1.2×	496	29.8k
Stefan Faderl United States	88	10.9k 0.6×	17.0k 0.9×	8.2k 0.7×	3.5k 0.4×	5.3k 1.2×	570	27.0k
Elias Jabbour United States	80	9.4k 0.5×	18.1k 1.0×	6.9k 0.6×	3.9k 0.5×	6.1k 1.4×	1.2k	25.4k
Zeev Estrov United States	82	10.5k 0.6×	13.3k 0.7×	11.7k 1.0×	2.4k 0.3×	4.8k 1.1×	669	26.3k
Moshe Talpaz United States	98	22.8k 1.2×	29.2k 1.6×	11.0k 0.9×	13.1k 1.5×	8.7k 2.0×	778	44.8k
Guillermo Garcia‐Manero United States	106	14.7k 0.8×	30.6k 1.6×	17.8k 1.5×	4.4k 0.5×	7.5k 1.7×	1.5k	44.1k
Francis J. Giles United States	105	15.8k 0.8×	20.4k 1.1×	15.0k 1.2×	6.3k 0.7×	9.3k 2.1×	786	41.9k

Countries citing papers authored by Srđan Verstovšek

Since Specialization

Citations

This map shows the geographic impact of Srđan Verstovšek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srđan Verstovšek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srđan Verstovšek more than expected).

Fields of papers citing papers by Srđan Verstovšek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srđan Verstovšek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srđan Verstovšek. The network helps show where Srđan Verstovšek may publish in the future.

Co-authorship network of co-authors of Srđan Verstovšek

This figure shows the co-authorship network connecting the top 25 collaborators of Srđan Verstovšek. A scholar is included among the top collaborators of Srđan Verstovšek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srđan Verstovšek. Srđan Verstovšek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oh, Stephen T., Ruben A. Mesa, Claire Harrison, et al.. (2023). Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Advances. 7(19). 5835–5842. 39 indexed citations

Masárová, Lucia, Prithviraj Bose, Naveen Pemmaraju, et al.. (2023). The role of therapy in the outcome of patients with myelofibrosis. Cancer. 129(18). 2828–2835. 3 indexed citations

Verstovšek, Srđan, Ivan Krečak, Florian H. Heidel, et al.. (2023). Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project. Biomedicines. 11(7). 1925–1925. 16 indexed citations

Pemmaraju, Naveen, et al.. (2023). Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leukemia & lymphoma. 64(6). 1063–1081. 22 indexed citations

Krečak, Ivan, Marko Skelin, & Srđan Verstovšek. (2023). Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera. Expert Review of Hematology. 16(5). 305–316. 5 indexed citations

Masárová, Lucia, Prithviraj Bose, Naveen Pemmaraju, et al.. (2022). Improved survival of patients with myelofibrosis in the last decade: Single‐center experience. Cancer. 128(8). 1658–1665. 26 indexed citations

Verstovšek, Srđan, et al.. (2021). Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy. SHILAP Revista de lepidopterología. 4(3). 117–128. 5 indexed citations

Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2020). Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American Journal of Hematology. 95(6). 594–603. 104 indexed citations

Chifotides, Helen T., Lucia Masárová, Mansour Alfayez, et al.. (2020). Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Advances. 4(21). 5336–5342. 37 indexed citations

10.

Alhuraiji, Ahmad, Kiran Naqvi, Yang O. Huh, et al.. (2017). Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure. Clinical Case Reports. 6(1). 155–161. 13 indexed citations

11.

Vaddi, Kris, et al.. (2016). Ruxolitinib: a targeted treatment option for patients with polycythemia vera. SHILAP Revista de lepidopterología. 1 indexed citations

12.

Fiskus, Warren, Srđan Verstovšek, Taghi Manshouri, et al.. (2013). Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells. Molecular Cancer Therapeutics. 12(5). 577–588. 83 indexed citations

13.

Manshouri, Taghi, Zeev Estrov, Alfonso Quintás-Cardama, et al.. (2011). Bone Marrow Stroma–Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor. Cancer Research. 71(11). 3831–3840. 80 indexed citations

14.

Fiskus, Warren, Srđan Verstovšek, Taghi Manshouri, et al.. (2011). Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells. Clinical Cancer Research. 17(23). 7347–7358. 83 indexed citations

15.

Verstovšek, Srđan, et al.. (2010). Myeloproliferative Neoplasms. Humana Press eBooks.

16.

Abdel‐Wahab, Omar, Taghi Manshouri, Jay Patel, et al.. (2010). Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias. Cancer Research. 70(2). 447–452. 227 indexed citations

17.

Garg, Ravin J., et al.. (2010). Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer. 117(4). 662–676. 13 indexed citations

18.

Ravandi, Farhad, E Estey, Dan Jones, et al.. (2008). Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. Journal of Clinical Oncology. 27(4). 504–510. 270 indexed citations

19.

Faderl, Stefan, Farhad Ravandi, Xuelin Huang, et al.. (2008). A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 112(5). 1638–1645. 151 indexed citations

20.

Tefferi, Ayalew, Jüergen Thiele, Attilio Orazi, et al.. (2007). Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 110(4). 1092–1097. 604 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact